Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm.

Molecular imaging is a rapidly emerging field, providing noninvasive visual quantitative representations of fundamental biological processes in intact living subjects. Fundamental biomedical research stands to benefit considerably from advances in molecular imaging, with improved molecular target selection, probe development and imaging instrumentation. The noninvasiveness of molecular imaging technologies will also provide benefit through improved patient care. Molecular imaging endpoints can be quantified, and therefore are particularly useful for translational research. Integration of the two disciplines of molecular imaging and molecular medicine, combined with systems-biology approaches to understanding disease complexity, promises to provide predictive, preventative and personalized medicine that will transform healthcare.

[1]  Ronald A. DePinho,et al.  Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development , 2006, Nature Reviews Drug Discovery.

[2]  M E Phelps,et al.  Positron emission tomography provides molecular imaging of biological processes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  S. Ziegler,et al.  Instrumentation and Data Acquisition , 2006 .

[4]  Sanjiv S Gambhir,et al.  Firefly luciferase enzyme fragment complementation for imaging in cells and living animals. , 2005, Analytical chemistry.

[5]  Adi F. Gazdar,et al.  Translational research comes of age , 1996, Nature Medicine.

[6]  Sanjiv S. Gambhir,et al.  How molecular imaging is speeding up antiangiogenic drug development , 2006, Molecular Cancer Therapeutics.

[7]  A. Signore,et al.  Receptor targeting agents for imaging inflammation/infection: where are we now? , 2006, The Quarterly Journal of Nuclear Medicine and Molecular Imaging.

[8]  R. Peters Nanoscopic medicine: the next frontier. , 2006, Small.

[9]  R. Blasberg Molecular imaging and cancer. , 2003, Molecular cancer therapeutics.

[10]  W. Richter Imaging biomarkers as surrogate endpoints for drug development , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  A. Papavassiliou Biochemistry versus molecular medicine: what should we be teaching our medical students? , 1999, Molecular medicine today.

[12]  S. Gambhir,et al.  Imaging Gene Expression: Concepts and Future Outlook , 2006 .

[13]  M. Sandler Diagnostic Nuclear Medicine , 2002 .

[14]  M. Mann,et al.  Proteomics to study genes and genomes , 2000, Nature.

[15]  E. Petricoin,et al.  The blood peptidome: a higher dimension of information content for cancer biomarker discovery , 2006, Nature Reviews Cancer.

[16]  K. Birmingham What is translational research? , 2002, Nature Medicine.

[17]  J M Hoffman,et al.  Molecular imaging in cancer: future directions and goals of the National Cancer Institute. , 2000, Academic radiology.

[18]  U. Bhalla,et al.  Complexity in biological signaling systems. , 1999, Science.

[19]  Daniel C Sullivan,et al.  Challenges and Opportunities for In Vivo Imaging in Oncology , 2002, Technology in cancer research & treatment.

[20]  Gregory S Karczmar,et al.  MRI of the tumor microenvironment , 2002, Journal of magnetic resonance imaging : JMRI.

[21]  Mingjun Zhang,et al.  Bio-Microarray Fabrication Techniques—A Review , 2006, Critical reviews in biotechnology.

[22]  Paul Workman,et al.  Translating basic cancer research into new cancer therapeutics. , 2002, Trends in molecular medicine.

[23]  S. Larson,et al.  The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development , 2005, Clinical Cancer Research.

[24]  L. Pauling,et al.  Sickle cell anemia a molecular disease. , 1949, Science.

[25]  Valentina Svicher,et al.  Novel drug resistance mutations in HIV: recognition and clinical relevance. , 2006, AIDS reviews.

[26]  M. Gassmann,et al.  From Genetically Altered Mice to Integrative Physiology. , 1998, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[27]  H. Kitano Systems Biology: A Brief Overview , 2002, Science.

[28]  C. Seidman,et al.  Molecular medicine in the 21st century , 2001, Internal medicine journal.

[29]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[30]  J. Pober,et al.  Obstacles facing translational research in academic medical centers , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  U. Alon Biological Networks: The Tinkerer as an Engineer , 2003, Science.

[32]  G. Tucker,et al.  Clinical Measurement in Drug Evaluation , 1991 .

[33]  Robert J Gillies,et al.  I2 imaging: cancer biology and the tumor microenvironment. , 2006, Cancer research.

[34]  D. Piwnica-Worms,et al.  Spying on cancer: molecular imaging in vivo with genetically encoded reporters. , 2005, Cancer cell.

[35]  N. Tamaki,et al.  Reduced 123I-BMIPP uptake implies decreased myocardial flow reserve in patients with chronic stable angina , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  Ralph Weissleder,et al.  Molecular imaging in the clinical arena. , 2005, JAMA.

[37]  D. Ganten,et al.  Transgenic animals as models for human disease. , 1995, Clinical and experimental hypertension.

[38]  Juewen Liu,et al.  Functional DNA nanotechnology: emerging applications of DNAzymes and aptamers. , 2006, Current opinion in biotechnology.

[39]  K Wienhard,et al.  Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas , 2001, The Lancet.

[40]  Michael E Phelps,et al.  Systems Biology and New Technologies Enable Predictive and Preventative Medicine , 2004, Science.

[41]  S. Huang,et al.  Dimensions of systems biology. , 2006, Reviews of physiology, biochemistry and pharmacology.

[42]  David A. Benaron,et al.  The Future of Cancer Imaging , 2004, Cancer and Metastasis Reviews.

[43]  C. Sigman,et al.  New science-based endpoints to accelerate oncology drug development. , 2005, European journal of cancer.

[44]  M. Kassiou,et al.  Imaging sigma receptors: applications in drug development. , 2007, Current pharmaceutical design.

[45]  G. Chiro Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. , 1987 .

[46]  S. Iyengar The quest for genes causing complex traits in ocular medicine: successes, interpretations, and challenges. , 2007, Archives of ophthalmology.

[47]  I. Tannock,et al.  The translational research chain: is it delivering the goods? , 2001, International journal of radiation oncology, biology, physics.

[48]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[49]  Sanjiv S Gambhir,et al.  Reporter gene imaging of protein-protein interactions in living subjects. , 2007, Current opinion in biotechnology.

[50]  T. O'Dorisio,et al.  Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. , 2002, Seminars in nuclear medicine.

[51]  S. Libutti,et al.  Molecular imaging of tumor angiogenesis , 2002, Journal of cellular biochemistry. Supplement.

[52]  A. Papavassiliou Clinical practice in the new era , 2001, EMBO reports.

[53]  Jonathon Bishop,et al.  Magnetic resonance imaging for detection and analysis of mouse phenotypes , 2005, NMR in biomedicine.

[54]  King Li,et al.  Combined vascular targeted imaging and therapy: A paradigm for personalized treatment , 2002, Journal of cellular biochemistry. Supplement.

[55]  D. Weatherall Towards molecular medicine; reminiscences of the haemoglobin field, 1960–2000 , 2001, British journal of haematology.

[56]  E. Ritchie,et al.  Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy. , 2006, Current cancer drug targets.

[57]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[58]  P. Price,et al.  Molecular imaging: what picture does it paint for future oncology? , 2002, Drug discovery today.

[59]  R. Salgia,et al.  Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer , 2006, Respirology.

[60]  W. Eckelman,et al.  Imaging of muscarinic receptors in the central nervous system. , 2006, Current pharmaceutical design.

[61]  J. Barrio,et al.  Assays for noninvasive imaging of reporter gene expression. , 1999, Nuclear medicine and biology.

[62]  E. Holland,et al.  Bioluminescence technology for imaging cell proliferation. , 2005, Current opinion in biotechnology.

[63]  E. Winzeler,et al.  Genomics, gene expression and DNA arrays , 2000, Nature.

[64]  R. S. Williams,et al.  Transgenic animals in integrative biology: approaches and interpretations of outcome. , 2000, Journal of applied physiology.

[65]  R. Blasberg,et al.  Reporter gene imaging: potential impact on therapy. , 2005, Nuclear medicine and biology.

[66]  Ronald G Blasberg,et al.  In vivo molecular‐genetic imaging , 2002, Journal of cellular biochemistry. Supplement.

[67]  D C Wight,et al.  Transgenic mice: a decade of progress in technology and research. , 1994, Mutation research.

[68]  Patrick S Daugherty,et al.  Microfluidic protein detection through genetically engineered bacterial cells. , 2006, Journal of proteome research.

[69]  M G Pomper,et al.  Molecular imaging: an overview. , 2001, Academic radiology.

[70]  D. Piwnica-Worms,et al.  Molecular imaging strategies for drug discovery and development. , 2006, Current opinion in chemical biology.